study of effects and of modifications in apoptosis regulators observed after stopping 5-asa treatment in patients with inactive ulcerative colitis

Conditions: Ulcerative Colitis

Summary: male or female, 18 years of age or older. ulcerative colitis described according usual criteria, diagnosed for at least 1 year. oral maintenance treatment with 5-aminosalicylic acid (5-asa) only for at least 3 months with a dosage of 2 to 3 g/day. clinical remission for at least 3 months (mayo clinic score) and endoscopic remission (endoscopic score of mayo clinic) at the inclusion. signed informed consent form.

inclusion criteria: * male or female, 18 years of age or older. * ulcerative colitis described according to usual criteria, diagnosed for at least 1 year. * oral maintenance treatment with 5-aminosalicylic acid (5-asa) only for at least 3 months with a dosage of 2 to 3 g/day. * clinical remission for at least 3 months (mayo clinic score) and endoscopic remission (endoscopic score of mayo clinic) at inclusion. * signed informed consent form. exclusion criteria: * patients allergic to aspirin or salicylates derivatives * patients taking the following treatments during the study will be excluded: corticosteroids (oral or rectal route), use of nsaid or aspirin, any form of sulfasalazine, mesalazine or 4-asa. * patients with known significant hepatic or known function abnormalities and/or creatine clearance ≤ 80 ml/min. * patients with history or physical examination findings indicative of active alcohol or drug abuse. * women who are pregnant or nursing. * patients with a history of disease, including mental/emotional disorder that would interfere with their participation in the study. * patients who participated in another clinical study in the last 3 months. * patients who are unable to comply with the requirements of the protocol * female of childbearing potential without efficacious contraception.

Eligibility criteria:
inclusion criteria: * male or female, 18 years of age or older. * ulcerative colitis described according to usual criteria, diagnosed for at least 1 year. * oral maintenance treatment with 5-asa only for at least 3 months with a dosage of 2 to 3 g/day. * clinical remission for at least 3 months (mayo clinic score) and endoscopic remission (endoscopic score of mayo clinic) at inclusion. * signed informed consent form. exclusion criteria: * patients allergic to aspirin or salicylates derivatives * patients taking the following treatments during the study will be excluded: corticosteroids (oral or rectal route), use of nsaid or aspirin, any form of sulfasalazine, mesalazine or 4-asa. * patients with known significant hepatic or known function abnormalities and/or creatine clearance ≤ 80 ml/min. * patients with history or physical examination findings indicative of active alcohol or drug abuse. * women who are pregnant or nursing. * patients with a history of disease, including mental/emotional disorder that would interfere with their participation in the study. * patients who participated in another clinical study in the last 3 months. * patients who are unable to comply with the requirements of the protocol * female of childbearing potential without efficacious contraception.

Keywords: ulcerative colitis for maintenance of remission